Novo Nordisk / Aradigm link on insulin device:
This article was originally published in Clinica
Executive Summary
Novo Nordisk and Aradigm plan the joint development of a pulmonary insulin delivery system, based on Aradigm's AerX drug delivery system. The deal includes other glucose-regulatory compounds as well as two other, unnamed and unrelated therapeutics. Novo gains worldwide rights to any of the resulting products and Aradigm gains $9 million in upfront payments and equity investment, with a total of $50 million in possible milestone payments thereafter. Aradigm is based in Hayward, California.